Celldex Therapeutics, Inc. (CLDX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$39.68+0.79%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CLDX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Complete enrollment and report topline data for barzolvolimab Phase 3 chronic spontaneous urticaria studies, advance cold urticaria and symptomatic dermographism studies, and prepare for potential co…
Stated as a priority in 2 of last 2 quarters. Management reported early completion of enrollment in Phase 3 CSU studies and expects topline data in late 2026, supporting a planned BLA filing in 2027. The company is actively preparing for potential commercialization. This trajectory matches management's stated focus on advancing barzolvolimab clinical development and commercialization readiness.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Enrollment completed six months ahead of guidance in Phase 3 CSU studies; topline data expected in Sept/Oct 2026; BLA submission planned for 2027.”
“Enrollment completed six months ahead of guidance in Phase 3 CSU studies; topline data anticipated in Q4 2026; BLA filing planned for 2027.”
Progress clinical development of CDX-622 targeting SCF and TSLP pathways, including Phase 1 proof of mechanism study in asthma and expansion into additional indications.
Stated as a priority in 2 of last 2 quarters. Management highlighted ongoing Phase 1 proof of mechanism study in asthma and plans to expand CDX-622 into additional indications. Positive Phase 1 data were presented, supporting continued development. The trajectory shows active clinical progress consistent with management's stated goals.
“Phase 1 CDX-622 proof of mechanism study in asthma ongoing; advancing expansion into additional indications including allergic rhinitis and food allergy.”
“CDX-622 Phase 1 proof of mechanism study initiated in January 2026; positive single ascending dose data presented in October 2025.”
Ensure cash, cash equivalents, and marketable securities are sufficient to meet working capital requirements and fund planned operations through 2028.
Stated as a priority in 5 of last 5 quarters. Cash, cash equivalents and marketable securities increased from $451.5 million at 2026-Q1 to $717.6 million at 2026-Q2, primarily due to a $323.8 million public offering in April 2026. Management consistently affirms sufficient liquidity to fund operations through 2028. The trajectory is delivering on this priority.
“Cash and marketable securities sufficient to fund operations through 2028.”
“Cash and marketable securities at March 31, 2026 plus $323.9M net proceeds from April 2026 offering sufficient to fund operations through 2028.”
“Cash and marketable securities at December 31, 2025 sufficient to fund operations through 2027.”
“Cash and marketable securities at September 30, 2025 sufficient to fund operations through 2027.”
“Cash and marketable securities at June 30, 2025 sufficient to fund operations through 2027.”
Control operating losses by managing research and development and general and administrative expenses amid increased clinical activities.
Stated as a priority in 2 of last 2 quarters. R&D expenses increased from $52.6 million in 2025-Q1 to $73.0 million in 2026-Q1, driven by barzolvolimab clinical and manufacturing costs and headcount growth. G&A expenses rose modestly from $10.8 million to $11.4 million over the same period due to commercial planning. Operating losses remain significant but expense growth aligns with management's stated investment in clinical and commercial activities.
“R&D expenses $67.5M, G&A expenses $13.1M, increases due to barzolvolimab clinical and commercial activities.”
“R&D expenses $73.0M, G&A expenses $11.4M, increases due to barzolvolimab clinical trial and commercial planning expenses.”
Oversee the planned retirement of CFO Sam Martin with a transition period through March 31, 2027.
Newly stated in 2026-Q2. Management announced the planned retirement of CFO Sam Martin with a transition period through March 31, 2027. No financial impact data is available yet to assess delivery on this priority.
“CFO Sam Martin plans to retire with transition period until March 31, 2027.”
Over the trailing year it converted 0.93x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
4 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.